Investor Presentation

TSXV:ATE 
 OTCQX:ATBPF Investor Presentation JANUARY 2017 Antibe Therapeutics Inc. ■ January 2017 - www.antibethera.com - TSXV:ATE 
 OTCQX:ATBPF ...
Author: Gervais Miles
3 downloads 0 Views 11MB Size
TSXV:ATE 
 OTCQX:ATBPF

Investor Presentation JANUARY 2017

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

TSXV:ATE 
 OTCQX:ATBPF

Forward-Looking Statements This presentation contains forward-looking information and statements which constitute “forward-looking information” under Canadian securities law and which may be material regarding, among other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations. Specific forward-looking information in this document includes, but is not limited to, statements with respect to the Company’s future operating and financial results, its research and development activities, its capital expenditure plans and the ability to execute on its future operating, investing and financing strategies. These forward-looking information and statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. Additional information regarding risk factors can be found in public disclosure records on SEDAR. Our statements of “belief” in respect of our product and partner product candidates are based primarily upon our results derived to date from our research and development program. We believe that we have a reasonable scientific basis upon which we have made such statements. It is not possible, however, to predict, based upon in vitro and animal studies whether a new therapeutic agent or technology will be proved to be safe and/ or effective in humans. We cannot assure that the particular results expected by us will occur. Any forward-looking statements and statements of “belief” represent our estimates only and should not be relied upon as representing our estimates as of any subsequent date. Except as required by law, we do not assume any obligation to update any forward looking statements or statements of “belief”. We disclaim any intention or obligation to update or revise any forward- looking statements or statements of “belief”, whether as a result of new information, future events or otherwise. Nothing herein should be construed as an Offering of securities of the Company in any jurisdictions.

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

2

TSXV:ATE 
 OTCQX:ATBPF

Antibe Therapeutics is a diversified biotech with two best-in-class divisions ■

Blockbuster drug platform of gamechanging therapeutics in pain and inflammation



Commercial, regenerative medicine business poised for global growth Antibes Seen from the Salis Gardens

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

Claude Monet (1840-1926)

3

TSXV:ATE 
 OTCQX:ATBPF

Investment Highlights Two key platforms: robust drug development pipeline combined with a dental regenerative medicine business ($10M revenue base) poised for global growth Biotech upside from potentially best-in-class therapeutics and devices, including a blockbuster potential game changer in the safe treatment of pain and inflammation
 Near-term catalysts from clinical milestones, commercial expansion and partnering activity to drive shareholder value in near- and long-term High-growth market opportunities: regenerative medicine is one of the fastest growing segments of healthcare; global market to reach US$57B by 2019(1) Leading expertise in pain, inflammation and regenerative medicine with clinical development strengths and deep industry relationships

(1) Source: BCC Research, Sept/14

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

4

TSXV:ATE 
 OTCQX:ATBPF

Antibe Therapeutics is a diversified biotech with two best-in-class divisions ■

Blockbuster drug platform of gamechanging therapeutics in pain and inflammation



Commercial, regenerative medicine business poised for global growth Antibes Seen from the Salis Gardens

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

Claude Monet (1840-1926)

5

TSXV:ATE 
 OTCQX:ATBPF

NSAIDs: Massive Market Opportunity

$12 Billion

NSAIDs = Non-Steroidal 
 Anti-Inflammatory Drugs

Global Market for NSAIDs


Among the Most Widely 
 Used Drugs in the World

Damage GIis Pervasive A Blockbuster Unmet Need

“The world needs a safer NSAID” - FDA, May 2010

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

6

TSXV:ATE 
 OTCQX:ATBPF

NSAIDs Have a Blockbuster Pedigree GI damage and CV safety from NSAIDs is “front and centre" on the radar screen of physicians.

Antibe Therapeutics Inc. ■ January 2017

Of the six drugs which hit $1 billion in sales in their first year,
 two were for the GI-toxicity issue with NSAIDs: Product

Company

Therapeutic Category

US Sales in 
 First Year

Sovaldi

Gilead

Hep C Antiviral

> $8.0B

Incivek

Vertex

Hep C Antiviral

$1.5B

Celebrex

Pharmacia

NSAID

$1.5B

Tecfidera

Biogen Idec

MS

$1.4B

Victoza

Novo Nordisk

Antidiabetic

$1.1B

Vioxx

Merck & Co

NSAID

$1.0B

- www.antibethera.com -

7

TSXV:ATE 
 OTCQX:ATBPF

Addressing an Unmet Need… ATB-346 was designed to deliver both GI and cardiovascular safety with nonaddictive pain relief.

Better CV Profile

ATB-346

Naproxen

NSAIDs

Meloxicam

Celebrex Bextra

- www.antibethera.com -

Better 
 GI 
 Profile

WITHDRAWN

Vioxx

Antibe Therapeutics Inc. ■ January 2017

The Need

WITHDRAWN

8

TSXV:ATE 
 OTCQX:ATBPF

Our Lead Drug: ATB-346 ■ Negligible GI damage: greatly superior to existing NSAIDs ■ No significant effect on blood pressure, unlike existing NSAIDs ■ Extensive, published, replicated data ■ Global IP with protection to ~2030 ■ Status: initial Phase 2 study completed successfully with strong results

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

9

TSXV:ATE 
 OTCQX:ATBPF

Superior GI Safety H2S physiological activities in the gut prevent NSAIDinduced GI Injury.

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

10

TSXV:ATE 
 OTCQX:ATBPF

Superior GI Safety ATB-346 produces negligible GI damage over the full range of human doses, unlike comparator NSAIDs.

*Rat study

Antibe Therapeutics Inc. ■ January 2017

Br J Pharmacol 2010; 159,1236-1246.

- www.antibethera.com -

11

TSXV:ATE 
 OTCQX:ATBPF

Rigorous Testing of GI Safety In conditions of increased susceptibility to gastric damage, the GI damage from comparator NSAIDs significantly increases whereas ATB-346 remains GI-safe.

*Rat study

Antibe Therapeutics Inc. ■ January 2017

Br J Pharmacol 2010; 159,1236-1246.

- www.antibethera.com -

12

TSXV:ATE 
 OTCQX:ATBPF

Additional Models Tested Impaired Mucosal Defence

Co-Morbidity

■ Sensory afferent nerves

■ Obesity

■ Inhibition of endogenous nitric

■ Advanced age

oxide

■ Rheumatoid arthritis

■ Inhibition of endogenous

■ Diabetes

hydrogen sulphide

■ Hypertension

■ Blockage of ATP-mediated

potassium channel

Antibe Therapeutics Inc. ■ January 2017

■ Pre-existing ulcers [healing]

- www.antibethera.com -

13

TSXV:ATE 
 OTCQX:ATBPF

No Significant Effect on Blood Pressure

15 Mean Arterial Pressure (mmHg)

Unlike other NSAIDs, ATB-346 does not have a significant effect on blood pressure; this result was confirmed in humans.

10

5

0

Vehicle

*Rat study

Antibe Therapeutics Inc. ■ January 2017

Naproxen

ATB-346

Br J Pharmacol 2010; 159,1236-1246.

- www.antibethera.com -

14

TSXV:ATE 
 OTCQX:ATBPF

Initial Phase 2 Successful with Strong Results ■ Hypothesis: Analysis strongly suggested

ATB-346 is much more potent and long-lasting than had been predicted from animal studies In the Phase 1 study, liver enzyme increases occurred in some subjects at high doses

■ Strong Phase 2 results:

ATB-346 was safe and well-tolerated Pain reduction observed well beyond the leading drugs in the market (naproxen and celecoxib) with much smaller dose ■ Subsequent development: Antibe will perform

dose-ranging and proof-of-concept Phase 2 studies demonstrating enhanced GI safety

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

15

TSXV:ATE 
 OTCQX:ATBPF

ATB-346: Future Development ■ Our development strategy is to perform two additional phase 2 clinical studies with

the goal of reaching a partnering event with Big Pharma within 18 months

■ Phase 2 dose ranging study: placebo-controlled study to validate effectiveness,

explore lower doses and establish go-to-market dose Clinical results anticipated by Q3/17

■ Phase 2 upper GI safety study: endoscopically-ascertained ulceration versus

comparator NSAID (naproxen)

Clinical results anticipated by Q2/18

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

16

TSXV:ATE 
 OTCQX:ATBPF

Clinical Development Pipeline Candidate

Target Indication

Pain & Inflammation

Partner

Market Niche

Status

Market Opportunity (USD)

ORAL THERAPEUTICS

ATB-346

Acute & chronic pain

Antibe

Osteoarthritis, rheumatoid arthritis, etc.

Phase 2

$12 Billion +

ATB-352

Acute pain

Antibe

Post-surgical pain, dental pain, gout, etc.

Pre-clinical

$2 Billion

ATB-340

Anti-thrombotic

Antibe

Stroke prevention, cancer prevention

Pre-clinical

$6 Billion +

Bone regeneration

Partnered(1)

Oral and maxillofacial surgery

Approved & launched

$150 Million

CGX-227

Bone regeneration

Antibe

Oral and maxillofacial surgery

Pre-clinical

$350 Million

CGX-443

Bone regeneration

Antibe

Oral and maxillofacial surgery

Pre-clinical

$250 Million

Bone regeneration

Partnered(2)

Oral and maxillofacial surgery

Clinical development

$1 Billion (US Market)

Regenerative Medicine Neomem FP™ (CGX-481)

URIST™

(CGX-276)

MEDICAL DEVICES

1) Antibe licensed the global distribution rights for Neomem FlexPlus™ for dental & craniofacial applications 2) Antibe licensed the exclusive Canadian distribution rights for URIST™ for dental & craniofacial applications from Induce Biologics in Jan/16

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

17

TSXV:ATE 
 OTCQX:ATBPF

ATB-352: Acute Pain Our next candidate, ATB-352, causes negligible GI damage in rats compared to ketoprofen (an NSAID prescribed for acute pain).

*Rat study

Antibe Therapeutics Inc. ■ January 2017

Nitric Oxide 2014 159, 1236-1246.

- www.antibethera.com -

18

TSXV:ATE 
 OTCQX:ATBPF

ATB-340: Aspirin Derivative Aspirin, but not ATB-340, causes significant bleeding ulcers in the rat stomach.

Single Administration of test drugs to rats

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

19

TSXV:ATE 
 OTCQX:ATBPF

Antibe Therapeutics is a diversified biotech with two best-in-class divisions ■

Blockbuster drug platform of gamechanging therapeutics in pain and inflammation



Commercial, regenerative medicine business poised for global growth Antibes Seen from the Salis Gardens

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

Claude Monet (1840-1926)

20

NEW - Neoderm demineralized particles offer an osteoinductive boost.p.10 Used either alone or as part of a composite bone graft, Applications (8 layers) allograft bone particulates supply a natural framework facilitating the attachment of osteogenic precursor cells. DynaGraft·D Premium Blend - This Cortical Mineralized/Demineralized blend the most popular allograft particles DynaGraft·D™ • Cell occlusive • Flexible and adaptable to • Human derived dermal graftscombines • Allows two tissue of remodeling. • Composed of used in dentistry, allvarying in a single vial! • Periodontal defects bone topographies. that are decellularized to immunoprivileged tissue. nutrient transfer e - (gel) 10-110-1050 • Allows • Maintains a threedimensional NEW remove cellular components • Extraction site repair • Exceptional tissue adherence. structure.RPM • Reduces inflammation - (gel) 10-110-1060 • Optimized flexibility DBM CORTICOand preserve the biological Vials Applications CANCELLOUS CORTICAL at the woundPREMIUM site. BLEND • Implant site development • Conservation of the • Guides the patient’s CANCELLOUS DEMINERALIZED ty) 10-120-1050 and rigidity properties that promote Granule size fibrous structure soft tissue to form • Contains laminin • side Sinus liftbeprocedures • Mineralized component in a • Either can revascularization and repair. utty) 10-120-1060 (mechanical strength). organized and1 cclaminin-54. Coronal the defectscomposite around immediate implants .5 cc 1tissue. cc 2 cc .5 cc 125-850 µm placed• towards graft • Neoderm acelluar dermis, soft tissue or bone • As a graft extender • Cell occlusive. • ECM contains two of • Resorbable. has the natural elasticity .5 cc 1 cc 2 cc 250-1000 µm .5 cc 1 cc 2 cc the three essential .5 cc 1 cc 2 cc • Minimal trimming Characteristics • Easily trimmed and • Osseous defects • Easy to cut to size, needed. human skin. Neoderm Demineralized with cancellousofis minimally bone biological components placed, bone wet or dry matrixshape and apply. .5 cc 1 cc 2 cc 500-1000 processedµm • Tightly adapts over required for healing. toand remove epidermal and DynaBlast™ is a composite graft product osteoconductive elements in a 2proprietary, • Gamma irradiated to sterilize. that• combines No need to tackosteoinductive or placed bone graft. cc 1000-2000 µm Demineralized bone matrix • Engineered1 ccto generate tissue dermal cells while preserving suture the material. reverse phase medium forwith superior • Fixated sutures orhandling. tacks. • No need to tack or of increased depth for rootfor superior the extracellular matrixinofa reverse DynaGraft·D™ is a first generation demineralized bone matrix phase medium • Incredibly tear resistant. suturehandling. the material. • Nonpyrogenic coverage and tissue bulking. the dermis. The grafts are • Sterile. • Suture pull out strength freeze-dried and sterilized. • Not synthetically nor between 290g and 350g. chemically cross-linked Applications Applications DynaBlast™

• Titanium frame to maintain space. • Engineered to withstand exposure. • Textured surface increases the stability of the membrane. • Impervious to bacteria. • Can be molded and shaped for space maintenance. • Can be trimmed to desired shape. • Titanium frame has little memory for easy placement.

e - (paste) - (paste) - (paste) ty) utty)

• On-lay grafting in ridge augmentation procedures. • Structural support when grafting 3 or 4-walled extraction sites.

TSXV:ATE 
 OTCQX:ATBPF

Citagenix: Poised for Global Growth…

CORTICOSyringes 10-210-1050 CANCELLOUS CORTICAL DEMINERALIZED DynaGraft·D DynaBlast CANCELLOUS • GTR • GTR • Replacement of damaged • Soft tissueRPM remodeling. • GTR DynaGraft·D™ DBM 10-210-1060 Granule size site repair or inadequate tissue for • Soft tissue grafting 0.5 cc syringe - (gel) 10-110-1050 • GBR • Extraction • GBR• Periodontal defects • GBR 10-210-1070 Extraction sitemixed repairwith the repair, reinforcement, • ImplantRaptos dehiscence defects .25cc .5 cc 1 cc cc tissue 1 cc .25cc .5 cc 1 cc .25cc .5 cc 1 ccRPM 200-850 µm .25cc •.5Soft particles may be• used alone or augmentation/ 1 cc syringe - (gel) 10-110-1060 DBM Applications 10-220-1030 • Implant site development or supplemental support • Sinus lift10-120-1050 procedures DBM Putty for osteoinductive potential. bulking. 1 cc jar - (putty) 1 cc 1 cc 1 cc 1 cc of soft tissue 850-1500 defects. µm CANCELLOUS 10-220-1040 • Moderate localized ridge defects• Sinus lift procedures • Gingival recession – 2.5 cc jar - (putty) 10-120-1060

■ Our commercial • Coronalsubsidiary, defects around immediate implants Citagenix • Miller’s Class II-III Inc. (“Citagenix), is the market leader in

www.raptos.com

Demineralized bonein matrix boneregenerative matrix3 with bone occurs to 4 monthscancellous (thin) 26 to 38 Demineralized weeks. 4 toputty 6 months. Epithelialization Canada dental medicine

Non resorbable membrane. and is poised for global growth

8 to 13 weeks. Resorption 4combines to 6 months 8 to 12 weeks. Accell Connexus is a high surface area demineralized matrix that(thick) incorporates ainand highly biocompatible DynaBlast™ is a composite graftbone product that (ABM) osteoinductive osteoconductive elements in a proprietary, Reverse Phase Medium (RPM) forphase robust handling. reverse medium for superior handling.

1

Availability

nefits

2

15x20, 20x30 & 30x40 mm

Applications

3

4

5

6

Demineralized bone 15x25, 20x30 & 30x40 mm 10x10, 10x20, 10x40 matrix 15x20, 20x30 & 30x40 mm 10x13, 10x25, 15x20 12x24, 13x19, 14x24, 17x25, & 20x40 in either thin demineralized 10x20, 10x30 & 20x40 mmin a reverse & 20x30phase mm medium for superior 20x25,13x18,handling. 25x30, 25x36, DynaGraft·D™ is a first generation bone matrix (0.5-1.0) or thick (1.0-1.5) 30x40 & 30x41 mm (Boxes of 2) Applications

Citagenix has a $10M revenue base and initiated a global growth strategy Deminralized bonehas matrix

DynaBlast™ eoinductive potential Accell Connexus Applications 0.5 cc syringe - (paste) 10-210-1050 DBM RPM DynaBlast ns at body temperature • When the10-210-1060 highest level of growth factors is desired DBM RPM 1 cc syringe - (paste) • Extraction repair is a demineralized DynaGraft·D bone matrix in a CMC carrier. ation C-GraftsitePutty™ • Osseous defects DynaGraft·D™ 3 cc syringe - (paste) 10-210-1070 Raptos bone blocks are •available in convenient • Implantmaterials dehiscence defects e • Periodontal defects In0.5 combination with less osteoinductive cc syringe - (gel) 10-110-1050 1 cc jarand - (putty) 10-220-1030 sizes shapes. Our cortico-cancellous blocks • Sinus lift procedures • Extraction site repair ABM • Implant site preparation or repair 1 cc syringe 10-110-1060 DBM Accell Connexus® and combine the stability of- (gel) a cortical • Moderate localized CANCELLOUS 2.5 ccwedge jar - (putty) 10-220-1040 ridge defects • Implant site development surface 10-310-1050 with the porosity of1 acccancellous jar - (putty) surface 7x7x1010-120-1050 mm 6x6x10 mm 6x12x12 mm 6x12x20 mm 10x10x10 mm e - (putty) • Sinus liftderived procedures Neomem® is a resorbable collagen membrane fromcollagen highly purified type I collagen NeoGuarde® is aBlock resorbable porcine dental This fibres type and Wedge Block Block membrane. Sponge Block Ifrom for osteointegration. Raptos 2.5 cc jardemineralized - (putty) C-Graft Putty™ 10-120-1060 - (putty) 10-310-1060 Applications

Raptos Bone blocks

Bovine resorbable collagen membrane Porcine collagen membrane Bone Graft Substitutes

Regenerative medicine is growing globally at 20%+

RPM

bovine type III Achilles collagen is manufactured using

• Coronal defects around immediate implants sponge block can betendon. compressed once The macromolecular pore size allows vital nutrient transfer while theaccording cellby occlusive membrane retards epithelium unique cross linkage technology. NeoGuarde sterilized Raptos bone blocks can be drilled for screw fixation and can beistrimmed toirradiation surgical needsand packaged in double pouches. Demineralized bone matrix putty 0.3 cc syringe CG-P03 C-Graft Putty™ rehydrated to adapt easilydown to the defect site.Longer in vivo stability. Optimized flexibility and rigidity for better space maintenance which allows for growth. 0.5 cc syringe CG-P05 Accell Connexus is asubstitute high Demineralized surface area demineralized bonedefects matrix (ABM) that incorporates a highly biocompatible Synthetic resorbable bone t bone matrix with cancellous bone • Periodontal orp i on desired tissue in-growth. es Reverse Phase Medium (RPM) for robust handling.• Extraction site repair 1.0 cc syringe CG-P10 on Synthetic resorbable bone substitute that uses the mineral building blocks naturally found in human bone. Features & Benefits Applications rpt iEclipse™ DynaBlast™ is a composite graft product that combines osteoinductive and osteoconductive elements in a proprietary, o Irradiated bone particulates, a natural scaffold for bone DBM regeneration Features & Benefits Applications s es Osteoinductive veneer graft 3.0unique cc syringe CG-P30 •for Implant site development CMC 4 week goes a step beyond with its combination of micro and macroporosity technology. reverse phase medium superior handling. 16 to 2 • Conservation of the fibrous structure (mechanical strength) • Guided Tissue Regeneration (GTR) s k e Raptos allograft mineralized bonecortical grafts bone offer an osteoconductive platform for bone •Granules: Gamma irradiated to sterilize / Nonpyrogenic • Guided Tissue • Sinus Regeneration lift procedures we Raptos Flex is a 1 mm thick osteoinductive, demineralized graft. this veneer graft regeneration and Raptos 6 to 38When hydrated, 2Regeneration 80% ß-tcp - 20% •HA — to Putty: 40% ß-tcp - 60% HAor suture the TIME Easy place with noApplications need toadapts tack material • Guided (GBR) demineralized particles offer anbe osteoinductive boost. eitheroralone as part of a composite bone graft, • Coronal defects around immediate implants becomes and easily to graft sites that would difficult toBone treat with Used particulate putty or grafts. These • Suture pull out strength between 290gpliable and 350g • Guided Bone Regeneration Features & Benefits E M T I facilitating the attachment of osteogenic precursor cells. bonesuited particulates supply a natural • Exceptional tissue during application characteristics makeadherence Raptosallograft Flex ideally for on lay grafting for the framework repair of shallow bone defects BMT BMT or bone loss. Cell occlusive - retards epithelium down growth •• Highest osteoinductive potential Accell Connexus Premium Blend This Cortical Mineralized/Demineralized blend combines two of the most popular allograft particles Applications DBM RPM Applications It can also be used to augment thin or missing bone over root form implants, and even for orbital floor repair - cases GUIDED BONE GUIDED TISSUE BD-30 DynaBlast™ • Flexible andtransfer adaptable to varying bone topographies ipse™ Granules 0.5•• to 1.0thickens mm at bodypore RPM temperature Macromolecular size allows nutrient • for When the highest of growth is desired —level REGENERATION KIT — — REGENERATION KIT — BS-60 used in dentistry, all infactors a single vial! where the veneer graft handling properties allow easy placement compared to particulate grafts and putties. Raptos Flex can be fixated with • Ridge preservation 0.5 cc syringe (paste) 10-210-1050 E1G002 Biocompatible /Cells occlusive /defects Tear resistant DynaBlast •• Resists irrigation with sutures or• tacks NEW BS-60 Can be • Osseous screws orfixated tacks and is available in convenient sizes. The grafts are sterilized using low-dose gamma irradiation and are freeze-dried so that they SS-65 • Deminralized Extraction site repair DBM RPM bone matrix Demineralized bone matrix with cancellous bone 1 cc syringe - (paste) 10-210-1060 • Ready to use E1G005 CORTICOVials • Extraction site repair • In combination with less osteoinductive materials Applications CANCELLOUS CORTICAL DEMINERALIZED PREMIUM BLEND have a shelf-life of 5 years• Sinus fromlifts the date of sterilization. CANCELLOUS NeoGuarde® ABM 3 cc syringe - (paste) E1G010 C-Graft Putty™ is a demineralized bone matrix in a •CMC carrier. C-Blast Putty™ isora repair composite graft product that combines osteoinductive and Implant • Implant site10-210-1070 preparation Granule size • Mineralized component in adehiscence defects Neomem® Accell Connexus® • Ridge augmentation 100-C15 115 ccApplications jar - (putty) 10-220-1030elements osteoconductive in a CMC carrier. ge) E1GS005 xdefects 25 mm NG1525 BB-46 MA-B1 .5 cc 1 cc 2 cc .5 cc 1 cc 125-850 µm composite graft • Sinus lift procedures • Osseous 0.5 - (putty) 10-310-1050 N1520 15ccx syringe 20 mm CANCELLOUS 2.5 cc•jar (putty) 10-220-1040 • Moderate localized ridge defects c syringes in a single sterile package) E1GS010 On lay grafting for the repair of shallow bone defects or bone loss. • As a graft extender • Periodontal defects .5 cc 1 ccLB-364 2 cc .5 cc 1 cc 2 cc 250-1000 µm .5 cc 1 cc 2 cc 1 cc syringe - (putty) 20 x•10-310-1060 30 mm thin or missing bone over root form implants. NG2030 ES-13 To augment ipse™ Granules 1.020 tox2.0 FG-1SCZ • Osseous defects 30mm mm N2030 MA-B1 MO-10 718-107 BD-158 FG-1SCZ FG-2SCZ .5 cc 1 cc 2 cc 500-1000 µm 707-2311 NeoGuarde® Orbital floor repair. Applications E2G020 LS-08 30 x• 40 mm NG3040 Applications 25 putty 30 x 40 Putty™ FG-2SCZ 20 xµm30 30| x6040 mm C-Graft Putty™ IM-15 15 xMIR-08 OBN-41000-2000 Easy to cut, shape and apply. • Cases whereC-Blast itN3040 is difficult toDemineralized place particulate grafts.substitute Synthetic resorbable bone bone matrix 1 cc 2 cc Eclipse™ Putty 40 BD-158 0.3 cc syringe CG-P03 0.3 cc syringe CB-P03 C-Graft Putty™ BD-30 LB-367 C-Blast Putty™ ge) E1P005 Accell Connexus is athe high surface area demineralized bone matrix (ABM) bone. that incorporates a highly biocompatible Synthetic resorbable bone substitute that uses mineral building blocks naturally found in human Eclipse™ FD-170 0.5 cc syringe CG-P05 0.5 cc syringe CB-P05 Eclipse™ DBM CMC • Periodontal Raptos Flex defects (1) Extraction siterobust repair handling. Phase Medium yringes in separate sterile packages) E1P010 goes a stepCG-P10 beyond with itsReverse unique combination of• (RPM) micro for and macroporosity technology. 1.0 cc syringe May be used alone or mixed with DBM 1.0 cc syringe CB-P10 • Extraction site repair defects www.membrane-neomem.com 10 x 10 mm 446001-R • Implant dehiscencePutty Raptos Flex may be used alone or in Neomem® for osteoinductive potential. Granules: 80% ß-tcp - 20% HA — 40% 60%lift HA 3.0 cc syringe CG-P30 3.0 cc syringe CB-P30 • Implant sitePutty: DBM CMC BioXclude™ isPH-79 aß-tcp 2nd•- Sinus generation and sterilized graft composed of allograft proceduresprocessed,30dehydrated LB-369 15development x 20 20100-C15 x 30 x 40 combination with other graft materials. Easily trimmed and placed, wet or dry.amnion and chorion tissue 15 x 15 mm 446003-R • Sinus(300 lift procedures • undergoes Moderate localizedPurion®, ridge defectsa proprietary tissue processing technology. BioXclude is sourced from the amniotic μm thick) that CORTICOCancellous Syringes Features Applications CANCELLOUS CORTICAL DEMINERALIZED 17&xBenefits 10 mm 446007-R • Coronal defects around immediate implants Applications CANCELLOUS Eclipse™ Granules 0.5 to 1.0 mm sac, the part of the placenta that developing fetus through term. Amniotic tissue consists of an PH-79 Needle Holder, 145 mm MO-10encloses Surgical Curette and protects the BD-30 Tissue Forceps MA-B1 Scalpel handle • Highest osteoinductive potential Accell Connexus Granule size • Ridgeinner preservation DBM RPM V and chorion contains collagen 0.25 cc (vial) E1G002 FG-1SCZ Iris layer Super-Cut scissors, Straight MIR-08chorion Periosteal Raspatory ES-13 Dissector amnion and an outer layer. Amnion contains collagen types III, IV and LS-08 Ruler • RPM thickens at body temperature •used When the highest level growthChisel factors 200-850 is desiredµm .25cc .5 cc 1 cc .25cc .5 cc 1 cc .25cc .5 cc 1 cc .25cc .5 cc 1 cc aft Substitutes • Extraction site repair FG-2SCZ Super-Cut Curved 718-107 Periodontal Raptos particles may bescissors, alone or mixed withof 0.5 cc (vial) E1G005 100-C15 Scalpel blades 707-2311 Double-ended explorer types I, 100-C15 III, IV, Iris V, VI. • Resists irrigation Membranes • Osseous defects Scalpel OBN-4 Gingivectomy Knives DBM Putty forBlades osteoinductive potential. • Sinus lifts FG-1SCZ Iris Super-Cut scissors, Straight BS-60 Tray for 10 instruments cc (vial) Straumann estimates E1G010 Bone Graft Substitutes (1) Stated in1 CAD; based on MRG and iData (using CAD:CHF rate of $1.35) • Ready to use 1 cc 1 cc 1 cc 1 cc 850-1500 µm • In combination with osteoinductive materials SS-65 Stainlesswith steel bone well, Ø 35 mm BD-158lessMicro Suture and Membrane Forceps Demineralized bone matrix cancellous bone • Ridge augmentation FG-2SCZ Iris Super-Cut scissors, Curved FD-170 Visit our C-Graft & C-BlastNeedle holder Features &E1GS005 Benefits Applications 0.5 cc (syringe) • Over block grafts and ridge ABM splits MA-B1 #5 Scalpel Handle BD-30 • Implant site preparationTissue or repair Forceps BB-46 Micro scalpel handle microsite for more BD-158 detailsMicro suture and membrane forceps • Osseousgraft defectsproduct that combines C-Blast Putty™ a composite osteoinductive and Connexus® 1.0 cc (2 x 0.5 cc syringes in a single sterile package) E1GS010 •369Covering • www.raptos.com Composed ofisAccell immunoprivileged tissue • SiteBS-60 preservation IM-15 Applicator for Bone Material Tray for 10 instruments LB-364, 367, Micro bladesthe lateral window • Periodontal defects osteoconductive elements in a CMC carrier. 0.5 cc syringe - (putty) 10-310-1050 - www.antibethera.com -

Dental Barrier Membranes r

r

High Quality Instruments

SERRATED

SERRATED

SHARP

SHARP

SHARP

Placental allograft membrane

Global Market for Oral Tissue Regeneration TUNGSTEN CARBIDE

TUNGSTEN CARBIDE

$550 - $675

MILLION

7

86

Eclipse™ Granules to•2.0 mm inflammation Antibe Therapeutics Inc.1.0 ■ January 2017 at the wound site Reduces 2.0 cc (vial)

10-310-1060 CMC Carrier • Contains cell adhesion factors and cytokines

1 cc syringeE2G020 - (putty)

BMT

• Bony defects around teeth and implants in sinus elevations •BMTMild gingival recession • Ridge augmentations

21

TSXV:ATE 
 OTCQX:ATBPF

Leveraging Our Synergies… Antibe has complementary resources that are being leveraged to transform Citagenix into a global growth story Present

Next 5 Years

Market leader in Canada with limited global presence

Global growth strategy with focus on U.S. and Europe

Canada

USA

Knowledge Leader

Clinical 
 Development

Comprehensive Product Portfolio

Strategy & Business Development

Distribution Infrastructure

Access to Capital Canada

ROW

$10M SALES BASE

Antibe Therapeutics Inc. ■ January 2017

USA

ROW

$50M SALES TARGET

- www.antibethera.com -

22

TSXV:ATE 
 OTCQX:ATBPF

Our Global Growth Strategy Footprint Expansion

Portfolio Expansion

Our strategy aims to leverage and replicate 
 the success of this leading Canadian 
 platform across the globe

Antibe will provide clinicians with the 
 portfolio of choice through innovation 
 and business development

2016

2017 Existing Products

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

2018

2019

New Products

23

TSXV:ATE 
 OTCQX:ATBPF

Citagenix Growth Strategy: Expanded ■ Citagenix’s global strategy aims to provide

an intelligent and streamlined experience for both distributors and oral clinicians Strategic Partnerships. Certain distributors can benefit greatly from Citagenix’s products to fill a gap in their offering

Footprint Expansion Our global growth strategy aims to leverage 
 and replicate the success in Canada with a focus on the U.S. and Europe

Intelligent Sales Management Layer. Recruitment of senior-level sales managers to support distributors (Launched in United States in October 2016) Systems Support. E-commerce and ERP platforms will streamline transactions and provide lots of tools for both distributors and end-users

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

24

TSXV:ATE 
 OTCQX:ATBPF

Citagenix Growth Strategy: Expanded ■ Citagenix now has additional resources that

it can leverage to consider a wider scope of product opportunities Internal Innovation. Citagenix is currently evaluating several innovative opportunities that have “best-in-class” potential

Portfolio Expansion Antibe will provide clinicians with the 
 portfolio of choice through innovation and 
 business development

Short Regulatory Approval. Dental biologics are generally registered through 510(k) pathway (approved within 6 months) Business Development. Greater access to capital supports in-licensing efforts ■ Our long-term goal is to become innovation

leaders in the dental biologics market

Antibe Therapeutics Inc. ■ January 2017

2016

2017 Existing Products

- www.antibethera.com -

2018

2019

New Products

25

TSXV:ATE 
 OTCQX:ATBPF

Clinical Development Pipeline Candidate

Target Indication

Pain & Inflammation

Partner

Market Niche

Status

Market Opportunity (USD)

ORAL THERAPEUTICS

ATB-346

Acute & chronic pain

Antibe

Osteoarthritis, rheumatoid arthritis, etc.

Phase 2

$12 Billion +

ATB-352

Acute pain

Antibe

Post-surgical pain, dental pain, gout, etc.

Pre-clinical

$2 Billion

ATB-340

Anti-thrombotic

Antibe

Stroke prevention, cancer prevention

Pre-clinical

$6 Billion +

Bone regeneration

Partnered(1)

Oral and maxillofacial surgery

Approved & launched

$150 Million

CGX-227

Bone regeneration

Antibe

Oral and maxillofacial surgery

Pre-clinical

$350 Million

CGX-443

Bone regeneration

Antibe

Oral and maxillofacial surgery

Pre-clinical

$250 Million

Bone regeneration

Partnered(2)

Oral and maxillofacial surgery

Clinical development

$1 Billion (US Market)

Regenerative Medicine Neomem FP™ (CGX-481)

URIST™

(CGX-276)

MEDICAL DEVICES

1) Antibe licensed the global distribution rights for Neomem FlexPlus™ for dental & craniofacial applications 2) Antibe licensed the exclusive Canadian distribution rights for URIST™ for dental & craniofacial applications from Induce Biologics in Jan/16

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

26

TSXV:ATE 
 OTCQX:ATBPF

Upcoming Milestones Antibe’s pipeline has several potential catalysts over the next 18 months, including additional Phase 2 data from ATB-346.

Antibe Therapeutics Inc. ■ January 2017

Expected Timeframe

Candidate

Milestone / Event

Q3/16

ATB-346

Initial Phase 2 Study Completed Successfully with Strong Results

Q3/17

ATB-346

Phase 2 Dose Ranging Study Data Available

Q3/17

ATB-352

Pre-clinical Toxicology Data Available

Q4/17

CGX-227

510(k) Regulatory Clearance

Q1/18

CGX-443

510(k) Regulatory Clearance

Q1/18

ATB-340

Pre-clinical Toxicology Data Available

Q2/18

ATB-346

Phase 2 GI Safety Study Data Available

- www.antibethera.com -

27

TSXV:ATE 
 OTCQX:ATBPF

Leadership Team & Board Leadership ■ Dan Legault JD
 CHIEF EXECUTIVE OFFICER

■ John Wallace PhD, MBA 
 CHIEF SCIENTIFIC OFFICER

■ Alain Wilson MBA
 CHIEF FINANCIAL OFFICER

■ David Vaughan PhD
 CHIEF DEVELOPMENT OFFICER

■ Uwe Tritthardt
 CHIEF EXECUTIVE OFFICER / CITAGENIX INC.

■ Scott Curtis MEng, CFA 
 VP, BUSINESS DEVELOPMENT

Board of Directors ■ Walt Macnee MBA

Chairman


VICE CHAIRMAN / MASTERCARD INC.

■ Roderick Flower PhD
 EMERITUS PROFESSOR OF PHARMACOLOGY / WILLIAM HARVEY RESEARCH INSTITUTE (WHRI)

■ Samira Sakhia MBA, CPA
 PRESIDENT / KNIGHT THERAPEUTICS INC.

■ Dan Legault JD
 CHIEF EXECUTIVE OFFICER / ANTIBE THERAPEUTICS INC.

■ John Wallace PhD, MBA 
 CHIEF SCIENTIFIC OFFICER / ANTIBE THERAPEUTICS INC.

■ Yung Wu 
 MANAGING DIRECTOR / NFQ VENTURES

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

28

TSXV:ATE 
 OTCQX:ATBPF

World-Class Advisors Our clinical and scientific advisory boards are comprised of world-class scientists, including a Nobel Laureate.

■ Dr. Andre Buret PhD
 CALGARY, ALBERTA

■ Dr. Francis Chan MD, PhD 
 HONG KONG, CHINA

■ Dr. Giuseppe Cirino PhD 
 NAPLES, ITALY

■ Dr. Peter B. Ernst DVM, PhD
 SAN DIEGO, CALIFORNIA

■ Dr. Derek Gilroy PhD
 LONDON, ENGLAND

■ Dr. Richard H. Hunt MD 
 OXFORD, ENGLAND

■ Dr. Louis J. Ignarro PhD
 LOS ANGELES, CALIFORNIA

■ Dr. Jane A. Mitchell PhD 
 LONDON, ENGLAND

■ Dr. Gilberto de Nucci MD, PhD
 SAO PAOLO, BRAZIL

■ Dr. Daniel K. Podolsky MD
 DALLAS, TEXAS

■ Dr. James Scheiman BS, MD
 ANN ARBOR, MICHIGAN

■ Dr. William Sessa PhD
 NEW HAVEN, CONNECTICUT

■ Dr. Philip M. Sherman MD
 TORONTO, ONTARIO

■ Dr. J. Carter Thorne MD, FRCP(C), FACP
 NEWMARKET, ONTARIO

■ Dr. Angel Lanas MD, DSc
 ZARAGOZA, SPAIN

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

29

TSXV:ATE 
 OTCQX:ATBPF

Capitalization Summary TSXV-ATE; OTCQX-ATBPF $0.30

Share Price(1)

$0.19

Shares Outstanding BASIC

112M

$0.25

Options & Warrants

45M

$0.20

Insider Ownership BASIC

45%

Market Capitalization(1)

$21M

Cash & Equivalents(2)

$4M

Convertible Debentures(2)

$3M

Sales (Trailing 12-Month)(2)

$10M

1,000

Share Price (CAD)

750

$0.15

500

$0.10

Volume (thousands)

Stock Symbols

250 $0.05

Feb-16 Apr-16 Jun-16 Jul-16 Sep-16 Nov-16 Jan-17

■ Convertible debenture holders include Knight Therapeutics Inc. (TSX:GUD) and the 


Bloom Burton Healthcare Lending Trust (1) As of market close January 11, 2017 (2) As at the end of Q2/F17 reporting period (Sept/16), including gross proceeds of $3M from Dec/16 equity financing

Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -

30

TSXV:ATE 
 OTCQX:ATBPF

Investor Presentation JANUARY 2017

Thank you! Antibe Therapeutics Inc. ■ January 2017

- www.antibethera.com -